US 6,147,197 AGranted

6-O-substituted erythromycin ketolides having antibacterial activity

OwnerYat Sun Or, Zhenkun Ma +4inventors

InventorsYat Sun Or, Zhenkun Ma, Richard F. Clark, Daniel T. Chu, Jacob J. Plattner, George Griesgraber

Life of this patent

Estimating the term…

Abstract

Antimicrobial compounds having the formula ##STR1## as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Claims4

Dependent claims

A compound having the formula V ##STR49## or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R.sup.b is selected from the group consisting of hydroxy, --O--C(O)--NH.sub.2 and --O--C(O)-imidazolyl;

R.sup.c is hydrogen or a hydroxy protecting group;
and
R is selected from the group consisting of
(1) methyl substituted with a moiety selected from the group consisting of
(a) --C.tbd.N,
(b) F,
(c) --CO.sub.2 R.sup.10 wherein R.sup.10 is C.sub.1 -C.sub.3 -alkyl or aryl substituted C.sub.1 -C.sub.3 -alkyl, or heteroaryl substituted C.sub.1 -C.sub.3 -alkyl,
(d) S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(e) NHC(O)R.sup.10 wherein R.sup.10 is as previously defined,
(f) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.3 -alkyl substituted with aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl, and
(j) substituted heteroaryl,
(2) C.sub.2 -C.sub.10 -alkyl,
(3) C.sub.2 -C.sub.10 -alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C.sub.1 -C.sub.3 -alkoxy,
(d) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(e) oxo,
(f) --N.sub.3,
(g) --CHO, and
(h) O--SO.sub.2 -(substituted C.sub.1 -C.sub.6 -alkyl),
(i) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are selected from the group consisting of
(i) hydrogen,
(ii) C.sub.1 -C.sub.12 -alkyl,
(iii) substituted C.sub.1 --C.sub.12 -alkyl,
(iv) C.sub.1 -C.sub.12 -alkenyl,
(v) substituted C.sub.1 -C.sub.12 -alkenyl,
(vi) C.sub.1 -C.sub.12 -alkynyl,
(vii) substituted C.sub.1 -C.sub.12 -alkynyl,
(viii) aryl,
(ix) C.sub.3 -C.sub.8 -cycloalkyl,
(x) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xi) substituted aryl,
(xii) heterocycloalkyl,
(xiii) substituted heterocycloalkyl,
(xiv) C.sub.1 -C.sub.12 -alkyl substituted with aryl,
(xv) C.sub.1 -C.sub.12 -alkyl substituted with substituted aryl,
(xvi) C.sub.1 -C.sub.12 -alkyl substituted with heterocycloalkyl,
(xvii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heterocycloalkyl,
(xviii) C.sub.1 -C.sub.12 -alkyl substituted with C.sub.3 -C.sub.8 -cycloalkyl,
(xix) C.sub.1 -C.sub.12 -alkyl substituted with substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xx) heteroaryl,
(xxi) substituted heteroaryl,
(xxii) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl, and
(xxiii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heteroaryl, or
R.sup.13 and R.sup.14 are taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which may be substituted with one or more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C.sub.1 -C.sub.3 -alkoxy,
(iv) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(v) oxo,
(vi) C.sub.1 -C.sub.3 -alkyl,
(vii) halo-C.sub.1 -C.sub.3 -alkyl, and
(vii) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkyl,
(j) --CO.sub.2 R.sup.10 wherein R.sup.10 is as previously defined,
(k) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(l) .dbd.N--O--R.sup.10 wherein R.sup.10 is as previously defined,
(m) --C.tbd.N,
(n) O--S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(o) aryl,
(p) substituted aryl,
(q) heteroaryl,
(r) substituted heteroaryl,
(s) C.sub.3 -C.sub.8 -cycloalkyl,
(t) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(u) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(v) heterocycloalkyl,
(w) substituted heterocycloalkyl,
(x) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(y) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(z) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(aa) .dbd.N--R.sup.9 wherein R.sup.9 is selected from the group consisting of:
(i) C.sub.1 -C.sub.6 -alkyl, optionally substituted with a substituent selected from the group consisting of
(aa) aryl,
(bb) substituted-aryl,
(cc) heteroaryl, and
(dd) substituted-heteroaryl,
(ii) aryl,
(iii) substituted-aryl,
(iv) heteroaryl,
(v) substituted-heteroaryl, and
(vi) heterocycloalkyl,
(bb) .dbd.N--NHC(O)R.sup.10 wherein R.sup.10 is as previously defined, and
(cc) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(4) C.sub.3 -alkenyl substituted with a moiety selected from the group consisting of
(a) halogen,
(b) --CHO,
(c) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(d) --C(O)--R.sup.9 where R.sup.9 is as previously defined,
(e) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(f) --C.tbd.N,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl,
(j) substituted heteroaryl,
(k) C.sub.3 -C.sub.7 -cycloalkyl, and
(l) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(5) C.sub.4 -C.sub.10 -alkenyl;
(6) C.sub.4 -C.sub.10 -alkenyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) C.sub.1 -C.sub.3 -alkoxy,
(c) oxo,
(d) --CHO,
(e) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(f) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(g) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(h) .dbd.N--O--R.sup.10 where R.sup.10 is as previously defined,
(i) --C.tbd.N,
(j) O--S(O).sub.n R.sup.10 where n is 0, 1 or 2 and R.sup.10 is as previously defined,
(k) aryl,
(l) substituted aryl,
(m) heteroaryl,
(n) substituted heteroaryl,
(o) C.sub.3 -C.sub.7 -cycloalkyl,
(p) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(q) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(r) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(s) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(t) .dbd.N--R.sup.9 wherein R.sup.9 is as previously defined,
(u) .dbd.N--NHC(O)R.sup.10 where R.sup.10 is as previously defined, and
(v) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(7) C.sub.3 -C.sub.10 -alkynyl;
and
(8) C.sub.3 -C.sub.10 -alkynyl substituted with one or more substituents selected from the group consisting of
(a) trialkylsilyl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl, and
(e) substituted heteroaryl.

129 more elements

A process for preparing a compound having the formula ##STR51## or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R.sup.b is selected from the group consisting of hydroxy, --O--C(O)--NH.sub.2 and --O--C(O)-imidazolyl;

R.sup.c is hydrogen or a hydroxy protecting group;
R is selected from the group consisting of
(1) methyl substituted with a moiety selected from the group consisting of
(a) --C.tbd.N,
(b) F,
(c) --CO.sub.2 R.sup.10 wherein R.sup.10 is C.sub.1 -C.sub.3 -alkyl, aryl substituted C.sub.1 -C.sub.3 -alkyl, or heteroaryl substituted C.sub.1 -C.sub.3 -alkyl,
(d) S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(e) NHC(O)R.sup.10 wherein R.sup.10 is as previously defined,
(f) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.3 -alkyl substituted with aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl, and
(j) substituted heteroaryl,
(2) C.sub.2 -C.sub.10 -alkyl,
(3) C.sub.2 -C.sub.10 -alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C.sub.1 -C.sub.3 -alkoxy,
(d) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(e) oxo,
(f) --N.sub.3,
(g) --CHO,
(h) O--SO.sub.2 -(substituted C.sub.1 -C.sub.6 -alkyl), and
(i) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are selected from the group consisting of
(i) hydrogen,
(ii) C.sub.1 -C.sub.12 -alkyl,
(iii) substituted C.sub.1 -C.sub.12 -alkyl,
(iv) C.sub.1 -C.sub.12 -alkenyl,
(v) substituted C.sub.1 -C.sub.12 -alkenyl,
(vi) C.sub.1 -C.sub.12 -alkynyl,
(vii) substituted C.sub.1 -C.sub.12 -alkynyl,
(viii) aryl,
(ix) C.sub.3 -C.sub.8 -cycloalkyl,
(x) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xi) substituted aryl,
(xii) heterocycloalkyl,
(xiii) substituted heterocycloalkyl,
(xiv) C.sub.1 -C.sub.12 -alkyl substituted with aryl,
(xv) C.sub.1 -C.sub.12 -alkyl substituted with substituted aryl,
(xvi) C.sub.1 -C.sub.12 -alkyl substituted with heterocycloalkyl,
(xvii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heterocycloalkyl,
(xviii) C.sub.1 -C.sub.12 -alkyl substituted with C.sub.3 -C.sub.8 -cycloalkyl,
(xix) C.sub.1 -C.sub.12 -alkyl substituted with substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xx) heteroaryl,
(xxi) substituted heteroaryl,
(xxii) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl, and
(xxiii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heteroaryl, or
R.sup.13 and R.sup.14 are taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which may be substituted with one or more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C.sub.1 -C.sub.3 -alkoxy,
(iv) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(v) oxo,
(vi) C.sub.1 -C.sub.3 -alkyl,
(vii) halo-C.sub.1 -C.sub.3 -alkyl, and
(vii) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkyl,
(j) --CO.sub.2 R.sup.10 wherein R.sup.10 is as previously defined,
(k) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(l) .dbd.N--O--R.sup.10 wherein R.sup.10 is as previously defined,
(m) --C.tbd.N,
(n) O--S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(o) aryl,
(p) substituted aryl,
(q) heteroaryl,
(r) substituted heteroaryl,
(s) C.sub.3 -C.sub.8 -cycloalkyl,
(t) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(u) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(v) heterocycloalkyl,
(w) substituted heterocycloalkyl,
(x) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(y) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(z) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(aa) .dbd.N--R.sup.9 wherein R.sup.9 is selected from the group consisting of:
(i) C.sub.1 -C.sub.6 -alkyl, optionally substituted with a substituent selected from the group consisting of
(aa) aryl,
(bb) substituted-aryl,
(cc) heteroaryl, and
(dd) substituted-heteroaryl,
(ii) aryl,
(iii) substituted-aryl,
(iv) heteroaryl,
(v) substituted-heteroaryl, and
(vi) heterocycloalkyl,
(bb) .dbd.N--NHC(O)R.sup.10 wherein R.sup.10 is as previously defined, and
(cc) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(4) C.sub.3 -alkenyl substituted with a moiety selected from the group consisting of
(a) halogen,
(b) --CHO,
(c) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(d) --C(O)--R.sup.9 where R.sup.9 is as previously defined,
(e) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(f) --C.tbd.N,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl,
(j) substituted heteroaryl,
(k) C.sub.3 -C.sub.7 -cycloalkyl, and
(l) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(5) C.sub.4 -C.sub.10 -alkenyl;
(6) C.sub.4 -C.sub.10 -alkenyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) C.sub.1 -C.sub.3 -alkoxy,
(c) oxo,
(d) --CHO,
(e) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(f) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(g) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(h) .dbd.N--O--R.sup.10 where R.sup.10 is as previously defined,
(i) --C.tbd.N,
(j) O--S(O).sub.n R.sup.10 where n is 0, 1 or 2 and R.sup.10 is as previously defined,
(k) aryl,
(l) substituted aryl,
(m) heteroaryl,
(n) substituted heteroaryl,
(o) C.sub.3 -C.sub.7 -cycloalkyl,
(p) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(q) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(r) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(s) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(t) .dbd.N--R.sup.9 wherein R.sup.9 is as previously defined,
(u) .dbd.N--NHC(O)R.sup.10 where R.sup.10 is as previously defined, and
(v) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(7) C.sub.3 -C.sub.10 -alkynyl;
and
(8) C.sub.3 -C.sub.10 -alkynyl substituted with one or more substituents selected from the group consisting of
(a) trialkylsilyl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl, and
(e) substituted heteroaryl;
the method comprising:
(a) treating a compound having the formula ##STR52## wherein R.sup.c is a hydroxy protecting group and R is as previously defined with a reagent combination selected from the group consisting of
(1) an alkali metal hydride and a phosgene reagent selected from the group consisting of phosgene, diphosgene and triphosgene under anhydrous conditions, followed by aqueous base catalyzed decarboxylation, and
(2) reaction with methanesulfonic anhydride in pyridine, followed by treatment with an amine base, to give the compound of formula V wherein R.sup.b is hydroxy;
(b) optionally treating the compound of formula V of step (a) wherein R.sup.b is hydroxy with an alkali metal hydride base and carbonyldiimidazole to give the compound of formula V wherein R.sup.b is --O--C(O)-imidazolyl;
(c) optionally treating the compound of formula V of step (b) wherein R.sup.b is --O--C(O)-imidazolyl with ammonia to give the compound of formula V wherein R.sup.b is --O--C(O)--NH.sub.2 ;
and
(d) optionally deprotecting and isolating the desired compound.

136 more elements

Dependencies are inferred from the claim text.

Facts

Application: 09/185,903Filed 4 Nov 1998 · division
Priority: 4 Sep 1996
Granted: 14 Nov 2000
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07H 17/08
Heterocyclic radicals containing only oxygen as ring hetero atoms: hetero rings containing eight or more ring members, e.g. erythromycins
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
Y02P 20/55
Improvements relating to the production of bulk chemicals: design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Family

Serial707,776Parent of this continuation-in-part · filed 4 Sep 1996
Serial888,350Parent of this division · filed 3 Jul 1997
US 5,866,549 AParent of this division
US 6,147,197 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

R.sup.c is hydrogen or a hydroxy protecting group;
and
R is selected from the group consisting of
(1) methyl substituted with a moiety selected from the group consisting of
(a) --C.tbd.N,
(b) F,
(c) --CO.sub.2 R.sup.10 wherein R.sup.10 is C.sub.1 -C.sub.3 -alkyl or aryl substituted C.sub.1 -C.sub.3 -alkyl, or heteroaryl substituted C.sub.1 -C.sub.3 -alkyl,
(d) S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(e) NHC(O)R.sup.10 wherein R.sup.10 is as previously defined,
(f) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.3 -alkyl substituted with aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl, and
(j) substituted heteroaryl,
(2) C.sub.2 -C.sub.10 -alkyl,
(3) C.sub.2 -C.sub.10 -alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C.sub.1 -C.sub.3 -alkoxy,
(d) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(e) oxo,
(f) --N.sub.3,
(g) --CHO, and
(h) O--SO.sub.2 -(substituted C.sub.1 -C.sub.6 -alkyl),
(i) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are selected from the group consisting of
(i) hydrogen,
(ii) C.sub.1 -C.sub.12 -alkyl,
(iii) substituted C.sub.1 --C.sub.12 -alkyl,
(iv) C.sub.1 -C.sub.12 -alkenyl,
(v) substituted C.sub.1 -C.sub.12 -alkenyl,
(vi) C.sub.1 -C.sub.12 -alkynyl,
(vii) substituted C.sub.1 -C.sub.12 -alkynyl,
(viii) aryl,
(ix) C.sub.3 -C.sub.8 -cycloalkyl,
(x) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xi) substituted aryl,
(xii) heterocycloalkyl,
(xiii) substituted heterocycloalkyl,
(xiv) C.sub.1 -C.sub.12 -alkyl substituted with aryl,
(xv) C.sub.1 -C.sub.12 -alkyl substituted with substituted aryl,
(xvi) C.sub.1 -C.sub.12 -alkyl substituted with heterocycloalkyl,
(xvii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heterocycloalkyl,
(xviii) C.sub.1 -C.sub.12 -alkyl substituted with C.sub.3 -C.sub.8 -cycloalkyl,
(xix) C.sub.1 -C.sub.12 -alkyl substituted with substituted C.sub.3 -C.sub.8 -cycloalkyl,
(xx) heteroaryl,
(xxi) substituted heteroaryl,
(xxii) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl, and
(xxiii) C.sub.1 -C.sub.12 -alkyl substituted with substituted heteroaryl, or
R.sup.13 and R.sup.14 are taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which may be substituted with one or more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C.sub.1 -C.sub.3 -alkoxy,
(iv) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkoxy,
(v) oxo,
(vi) C.sub.1 -C.sub.3 -alkyl,
(vii) halo-C.sub.1 -C.sub.3 -alkyl, and
(vii) C.sub.1 -C.sub.3 -alkoxy-C.sub.1 -C.sub.3 -alkyl,
(j) --CO.sub.2 R.sup.10 wherein R.sup.10 is as previously defined,
(k) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(l) .dbd.N--O--R.sup.10 wherein R.sup.10 is as previously defined,
(m) --C.tbd.N,
(n) O--S(O).sub.n R.sup.10 wherein n is 0, 1 or 2 and R.sup.10 is as previously defined,
(o) aryl,
(p) substituted aryl,
(q) heteroaryl,
(r) substituted heteroaryl,
(s) C.sub.3 -C.sub.8 -cycloalkyl,
(t) substituted C.sub.3 -C.sub.8 -cycloalkyl,
(u) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(v) heterocycloalkyl,
(w) substituted heterocycloalkyl,
(x) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(y) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(z) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(aa) .dbd.N--R.sup.9 wherein R.sup.9 is selected from the group consisting of:
(i) C.sub.1 -C.sub.6 -alkyl, optionally substituted with a substituent selected from the group consisting of
(aa) aryl,
(bb) substituted-aryl,
(cc) heteroaryl, and
(dd) substituted-heteroaryl,
(ii) aryl,
(iii) substituted-aryl,
(iv) heteroaryl,
(v) substituted-heteroaryl, and
(vi) heterocycloalkyl,
(bb) .dbd.N--NHC(O)R.sup.10 wherein R.sup.10 is as previously defined, and
(cc) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(4) C.sub.3 -alkenyl substituted with a moiety selected from the group consisting of
(a) halogen,
(b) --CHO,
(c) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(d) --C(O)--R.sup.9 where R.sup.9 is as previously defined,
(e) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(f) --C.tbd.N,
(g) aryl,
(h) substituted aryl,
(i) heteroaryl,
(j) substituted heteroaryl,
(k) C.sub.3 -C.sub.7 -cycloalkyl, and
(l) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(5) C.sub.4 -C.sub.10 -alkenyl;
(6) C.sub.4 -C.sub.10 -alkenyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) C.sub.1 -C.sub.3 -alkoxy,
(c) oxo,
(d) --CHO,
(e) --CO.sub.2 R.sup.10 where R.sup.10 is as previously defined,
(f) --C(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(g) --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(h) .dbd.N--O--R.sup.10 where R.sup.10 is as previously defined,
(i) --C.tbd.N,
(j) O--S(O).sub.n R.sup.10 where n is 0, 1 or 2 and R.sup.10 is as previously defined,
(k) aryl,
(l) substituted aryl,
(m) heteroaryl,
(n) substituted heteroaryl,
(o) C.sub.3 -C.sub.7 -cycloalkyl,
(p) C.sub.1 -C.sub.12 -alkyl substituted with heteroaryl,
(q) NHC(O)R.sup.10 where R.sup.10 is as previously defined,
(r) NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined,
(s) .dbd.N--NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are as previously defined,
(t) .dbd.N--R.sup.9 wherein R.sup.9 is as previously defined,
(u) .dbd.N--NHC(O)R.sup.10 where R.sup.10 is as previously defined, and
(v) .dbd.N--NHC(O)NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are as previously defined;
(7) C.sub.3 -C.sub.10 -alkynyl;
and
(8) C.sub.3 -C.sub.10 -alkynyl substituted with one or more substituents selected from the group consisting of
(a) trialkylsilyl,
(b) aryl,
(c) substituted aryl,
(d) heteroaryl, and
(e) substituted heteroaryl.

129 more elements

Facts

Application

09/185,903Filed 4 Nov 1998 · division

Priority

4 Sep 1996

Granted

14 Nov 2000

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07H 17/08
Heterocyclic radicals containing only oxygen as ring hetero atoms: hetero rings containing eight or more ring members, e.g. erythromycins
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
Y02P 20/55
Improvements relating to the production of bulk chemicals: design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups